Feasibility of using contrast-free quantitative magnetic resonance imaging for liver sparing stereotactic ablative body radiotherapy.

Background And Purpose: Tumours in the liver often develop on a background of liver cirrhosis and impaired liver function. As a result, radiotherapy treatments are limited by radiation-induced liver disease, parameterised by the liver mean dose (LMD). Liver function is highly heterogeneous, especially in liver cancer, but the use of LMD does not take this into account.

Time to level up treatment for less survivable cancers.

Dramatic regional variations in outcomes for patients with less survivable cancer (lung, pancreatic, brain, oesophageal and gastric) have been highlighted in a report published by MSD. This editorial examines this report and considers the implications for UK cancer strategy.

Bladder Preservation for Muscle-Invasive Bladder Cancer With Variant Histology.

A growing body of evidence has shown bladder-preservation with chemo-radiotherapy achieves comparable survival to Radical Cystectomy (5-year OS 50%-70%) and superior quality of life outcomes for patients with muscle-invasive urothelial carcinoma of the bladder (UC). However, up to 55% of patients harbor variant histology and in this review we aim to clarify the role of bladder-preservation for this group. We first draw the distinction between urothelial carcinoma with divergent differentiation (UCDD) and non-urothelial carcinoma (NUC).